This page shows the latest Eloctate news and features for those working in and with pharma, biotech and healthcare.
A number of treatments on the market are designed to replace factor VII, including both short-acting and newer long-acting versions such as Shire’s Adynovate, Biogen’s Eloctate,
s Eloctate, Bayer’s Kovaltry and CSL Behring’s Afstyla.
There was bad news for Genzyme’s blood disorders unit, however. Long-acting haemophilia A drug Eloctate – acquired as part of Sanofi’s $11.9bn acquisition of Bioverativ last year – succumbed ... Sanofi took a hefty 1.8bn charge on its books in
Takeda’s Shire unit already has a long-acting factor VIII product on the market in Adynovate, as does Sanofi with Eloctate from its recent Bioverativ acquisition, Bayer with Kovaltry, and
Haemophilia and other rare blood diseases have become key therapeutic targets for Sanofi in the wake of its acquisition of Bioverativ – which gave it long-acting clotting factor therapies Eloctate and
While growth for haemophilia treatments Eloctate and Alprolix – acquired as part of Sanofi’s $11.9bn acquisition of Bioverativ last year – remained fairly sluggish, the quarter was marked first sales contribution ... Eloctate and Alprolix grew 4%
More from news
Approximately 3 fully matching, plus 28 partially matching documents found.
s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as well as a pipeline of candidates focused on rare blood ... disorders. During 2016 Eloctate and Alprolix
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...